Stoke Therapeutics

top of page

Stoke Therapeutics' CEO Ed Kaye discusses today's partnership news with Biogen on Zorevunersen for the treatment of Dravet syndrome

He describes the design of the global pivotal study, which will be initiating soon, why Stoke chose Biogen as a partner, and how today's...

Company News

Feb 18

Stoke Therapeutics' CEO Ed Kaye on using RNA medicines to upregulate protein expression, and the company's progress in Dravet Syndrome

He describes the unique science that Stoke was founded on, how phase 1/2a data in Dravet appears to show they are reversing this genetic...

Company News

Aug 5, 2024

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.

Learn more about Allucent

bottom of page

Stoke Therapeutics' CEO Ed Kaye discusses today's partnership news with Biogen on Zorevunersen for the treatment of Dravet syndrome

Stoke Therapeutics' CEO Ed Kaye on using RNA medicines to upregulate protein expression, and the company's progress in Dravet Syndrome

Follow BiotechTV

Sponsors

Sponsor Spotlight